PG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PG is not a good buy right now for an impatient buyer. The stock is pressing into near-term resistance (~150.7) with only modest fundamental momentum (FY2026 Q2 EPS and net income down YoY) and heavy insider selling, which makes the risk/reward unattractive for a “buy now” entry. I would hold (or wait for either a pullback toward ~147.7 support or a clean breakout above ~150.7–152.6 with follow-through).
Pre-market ~150.2 (+0.2%) while the broader market is slightly risk-off (S&P 500 pre-market -0.37%). Momentum is constructive: MACD histogram is positive (0.593) and expanding, which supports an ongoing upswing. RSI(6) ~65.9 is still technically “neutral” but close to overbought, implying upside may be near-term constrained unless price breaks out. Moving averages are converging, consistent with a decision point rather than a strong trend. Key levels: Pivot 147.679 is the nearby “line in the sand” support; below that, S1 144.627 then S2 142.741. Resistance is close: R1 150.731 (just above current pre-market), then R2 152.617. With price sitting just under R1 and RSI elevated, the current setup looks more like ‘late entry into resistance’ than a fresh, low-risk buy point. Pattern-based outlook provided is also slightly negative over 1W/1M (-3.5% / -2.45% odds-weighted).
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Recent earnings commentary appears to have reassured multiple Wall Street firms (several upgrades/price target increases on 2026-01-23), supporting the idea of a 2H improvement narrative.
Defensive “dividend-stability” appeal remains a tailwind in choppy markets (news flow highlights PG as a long-term dividend compounder).
Technical momentum is positive (expanding MACD) and a breakout above ~150.7 could trigger a push toward ~152.6.
Insider activity is a major red flag: insiders are net sellers and selling spiked sharply over the last month, which typically pressures near-term upside confidence.
Growth concerns are still active: TD Cowen’s downgrade (to Hold) cited subdued organic growth and weaker pricing power, plus consumer pressure in certain cohorts.
Price is currently near resistance (~150.
with RSI near overbought—this is a tougher spot for an impatient entry because upside may be limited without a clean breakout.
The pattern-based short-term forecast provided leans negative over the next week/month.
Latest quarter: FY2026/Q2. Revenue rose to $22.208B (+1.49% YoY), but profitability weakened: Net income fell to $4.247B (-6.82% YoY) and EPS to $1.78 (-5.32% YoY). Gross margin slipped to 52.03% (-0.93% YoY). Net/net: top-line is still growing, but margins/earnings are trending down, which supports the ‘stable but not accelerating’ view and limits near-term multiple expansion unless growth re-accelerates.
Recent trend: A cluster of upgrades and price target hikes hit after the Q2 print (UBS to $170 Buy; BofA to $171 Buy; JPM upgraded to Overweight PT $165; DBS upgraded to Buy $167; Wells Fargo reiterated Overweight with higher PT). Offsetting this, TD Cowen downgraded to Hold (PT $156, raised from $150) citing a slower recovery and subdued growth outlook. Wall Street ‘pros’ case: re-acceleration potential in organic sales and margin improvement, plus a potential re-rating back toward historical valuation. ‘Cons’ case: limited pricing power, volume/consumer pressure, and a slower-than-expected growth recovery—consistent with the downgrade and the weaker YoY earnings in the latest quarter.
Influential trading (Congress): In the last 90 days, Congress trades were balanced (4 buys vs 4 sells), with purchase sizes larger (median ~$4.1M) than sales (median ~$0.8M). This reads as mild support from buy sizing, but the balanced count makes it non-decisive.
